What is the TaiMed Biologics Inc. stock price forecast?

TaiMed Biologics Inc. is currently trading at $57.20. View real-time AI analysis on Alpha Lenz.

What is TaiMed Biologics Inc. insider trading activity?

View the latest insider trading data for TaiMed Biologics Inc. on Alpha Lenz.

What is TaiMed Biologics Inc.'s P/E ratio?

View TaiMed Biologics Inc.'s valuation metrics on Alpha Lenz.

TaiMed Biologics Inc.

TWSE · 4147

NT$57.20+0.40(+0.70%)

Ask about TaiMed Biologics Inc.'s future dividend policy...

Alpha Chat Insight

“TaiMed Biologics Inc.'s ROE is -4.3%. Explore profitability and growth together.”

Ask for details →

Company Overview

TaiMed Biologics Inc. is a biotechnology company specializing in the development, manufacture, and commercialization of novel therapies for infectious diseases, with a core focus on HIV treatment. Founded in 2007 and headquartered in Taipei City, the company is recognized for bringing to market Trogarzo®, the first monoclonal antibody drug approved in the US and EU for HIV, marking a significant milestone in both global HIV care and Taiwan’s biopharmaceutical sector. TaiMed Biologics also pursues innovation with its monoclonal antibody pipeline, including TMB-365 and TMB-380 for HIV prevention and treatment, and antibody-drug conjugates targeting cancer. Besides proprietary drug development, the company provides contract development and manufacturing (CDMO) services, leveraging its cGMP-certified facility to support external partners with process development, analytical validation, and large-scale production for biologics. TaiMed Biologics plays an influential role in Taiwan’s life sciences industry through its collaborations, regulatory achievements, and dedication to addressing unmet medical needs in the field of advanced biologics.

CEOMr. Chin-Ming Chang Ph.D.

Websitehttps://www.taimedbiologics.com

SectorHealthcare

IndustryBiotechnology

Company Statistics

FY 2025

Profile

N/AMarket Cap

NT$611.35MRevenue

0.00Shares Out

0Employees

Margins

42.44%Gross

-0.56%EBITDA

-31.84%Operating

-27.44%Pre-Tax

-27.44%Net

Valuation

N/AP/E

N/AP/B

N/AEV/Sales

N/AEV/EBITDA

N/AP/FCF

Growth (CAGR)

2.78%Rev 3Yr

-3.29%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-3.42%ROA

-4.26%ROE

-3.20%ROIC

Financial Health

NT$898.38MCash & Cash Equivalents

NT$54.67MNet Debt

24.71%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“TaiMed Biologics Inc.'s ROE is -4.3%. Explore profitability and growth together.”

Ask for details →

Frequently Asked Questions

TaiMed Biologics Inc. (ticker: 4147) is a company listed on TWSE in the Healthcare sector (Biotechnology).

The current price is 57.2 with a P/E ratio of -x and P/B of -x.

ROE is -4.26% and operating margin is -31.84%. Annual revenue is $611M.